Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

36 results about "Catenin Proteins" patented technology

Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells. The first two catenins that were identified became known as α-catenin and β-catenin. A-catenin can bind to β-catenin and can also bind actin.

Cosmetic use of a composition for improving white hair

PendingCN122320809AGraying hairsMelanin synthesis
This invention relates to the cosmetic use of a composition for improving gray hair. The composition of this invention promotes melanin synthesis in hair by activating the Wnt / β-catenin signaling pathway, thereby exhibiting significant and excellent effects in inhibiting, preventing, improving, alleviating, delaying, or treating gray hair (white hair syndrome).
Owner:LG HOUSEHOLD & HEALTH CARE LTD

Peptides having activity to promote hair growth and inhibit hair loss and uses thereof

The present invention relates to a peptide having an activity of promoting hair growth or preventing or inhibiting hair loss. The peptide of the present invention has an activity of promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating a cell proliferation-related signal protein in human dermal papilla cells, activating β-catenin, improving expression levels of factors downstream of β-catenin, down-regulating expression levels of hair-loss protein DKK-1, and increasing expression of keratins in hair outer root sheath cells (HORSC).
Owner:CAREGEN

Beta-catenin-binding peptides and peptidomimetics and uses thereof

PCT designated stageWO2026038952A1Peptide/protein ingredientsAnimals/human peptidesBinding peptideCatenin Proteins
The invention relates to β-catenin-binding peptides and peptidomimetics comprising an amino acid sequence ESILDEHXQRVW or EYPESILDEHXQRVWR, wherein X is L, M, I, F, Y, W or C, or a variant of said amino acid sequences, and to uses thereof.
Owner:STICHTING VU

Hair follicle regeneration nano activator as well as preparation method and application thereof

The invention relates to the technical field of biological medicines, and particularly provides a hair follicle regeneration nano activator as well as a preparation method and application thereof. The activator comprises a first coupling monomer and a second coupling monomer, an oligonucleotide sequence of the first coupling monomer and an oligonucleotide sequence of the second coupling monomer are at least partially complementary and form a double-chain structure through base pairing, the first coupling monomer is formed by coupling a first polypeptide and a first ssDNA, and the second coupling monomer is formed by coupling a second polypeptide and a second ssDNA. The second coupling monomer is formed by coupling a second polypeptide and a second ssDNA; wherein the first polypeptide and the second polypeptide are both specifically targeted to beta-catenin protein. The polypeptide-DNA-polypeptide dimer has a polypeptide-DNA-polypeptide sandwich-type dimer structure, can be specifically combined with beta-catenin in stem cells, only regulates and controls a Wnt / beta-catenin pathway, does not generate non-specific influence on other pathways, and can efficiently activate a hair follicle regeneration related signal pathway and promote a hair follicle development biological process.
Owner:HUNAN UNIV

Multivalent FZD4, WNT co-receptor, and VEGF receptor molecules and uses thereof

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.
Owner:MERCK SHARP & DOHME LLC +1

Beta-catenin depot detection and modulation assays

The present application provides, in some aspects, methods of determining a beta-catenin depot and uses thereof, for example, to identify compounds that modulate, such as increase, a beta-catenin depot in a cell. Also provided herein, in other aspects, are related methods, such as methods of identifying compounds for the treatment of beta-catenin associated diseases, kits, and useful compounds identified thereby.
Owner:DEWPOINT THERAPEUTICS INC

Composition for preventing hair loss or promoting hair growth

The present invention relates to a composition for preventing hair loss or promoting hair growth, containing an ingredient for promoting hair growth or delaying hair loss. In order to confirm this, the wnt / beta-catenin signaling pathway activity promoting effect, the hair papilla cell proliferation effect, and the beta-catenin protein expression amount increasing effect wnt / beta-catenin signaling pathway activity promoting effect, the hair papilla cell proliferation effect and the beta-catenin protein expression amount increasing effect have been confirmed by in vitro experiments. Further, it is confirmed that a good result is exhibited in a researcher evaluation by clinical photograph shooting and an evaluation by hair image shooting after use, thereby exhibiting a high effect of preventing hair loss and / or hair growth. In view of these comprehensive results, the composition of the present invention has excellent effects of preventing hair loss and / or promoting hair growth.
Owner:LG HOUSEHOLD & HEALTH CARE LTD

Peptides that promote hair growth and inhibit hair loss and their uses

ActiveCN120019063BMedicineDermal papillae
This invention relates to peptides that promote hair growth or prevent or inhibit hair loss. The peptides of this invention promote the proliferation of follicular dermal papilla cells (HFDPC) and human pilosebaceous dermal sheath cells (HHORSC), upregulate the expression of β-catenin secondary factor in HFDPC, upregulate the expression of growth factors in HFDPC, and downregulate the expression level of Dickkopf-1 (DKK-1), a protein that causes hair loss.
Owner:CAREGEN

RNA aptamer conjugates and uses thereof

Pharmaceutical compositions and compounds comprising a phosphorothioated CpG oligodeoxynucleotide linked to a DNA oligonucleotide that is hybridized an RNA aptamer are useful in methods of treating cancer (such as leukemia) and methods of inhibiting DNA methyltransferase. In embodiments, the RNA aptamer binds to an intracellular target such as DNMT1, NF-kB, RUNX1, MYC, MYB, ETS, PAX5, MDM2, F0XM1, PU.l, STAT3, STATS. STAT6, FAD, ATP5B, or beta-catenin.
Owner:CITY OF HOPE

Peptides that promote hair growth and inhibit hair loss and their uses

ActiveCN120019062BDermal papillaeCatenin Proteins
This invention relates to peptides with activity that promotes hair growth or prevents or inhibits hair loss. The peptides of this invention promote the proliferation of human follicular dermal papilla cells (HFDPC), activate cell proliferation-related signaling proteins and β-catenin in HFDPC, enhance the expression levels of downstream genes of β-catenin, downregulate the expression level of the hair loss protein DKK-1, increase the expression of keratin in hair follicle outer root sheath cells (HORSC), and upregulate the expression of transcription factors involved in cell activation in germinal stromal cells (GMC).
Owner:CAREGEN

Peptides having activity to promote hair growth and inhibit hair loss and uses thereof

ActiveCN120035599BCosmetic preparationsHair cosmeticsMedicineHair root sheath
The present invention relates to peptides having an activity of promoting hair growth or preventing or inhibiting hair loss. The peptides according to the present invention promote proliferation of hair follicle dermal papilla cells (HFDPC) and human hair root sheath cells (HHORSC), upregulate expression of a beta-catenin secondary factor in hair follicle dermal papilla cells (HFDPC), and upregulate expression of a growth factor.
Owner:CAREGEN

Deep sea naphthyridine pyran alkaloid compound and application thereof in preparation of medicine for preventing or treating bone metabolic diseases

PendingCN121735963AOrganic chemistrySkeletal disorderEndocrine bone diseaseOsteitis
The invention belongs to the technical field of biological medicines, and discloses a deep-sea naphthyridine pyran alkaloid compound, a preparation method thereof and application of the deep-sea naphthyridine pyran alkaloid compound in preparation of medicines for preventing and / or treating bone metabolism diseases, particularly bone metabolism diseases such as bone fracture, osteoporosis, rickets, endocrine bone diseases, osteitis deformans and hereditary bone diseases. The new skeleton compound composed of 2, 7-naphthyridinone and pyranol is found for the first time, can promote mineralization of osteogenesis by targeting beta-catenin protein so as to achieve an obvious effect of promoting fracture repair, has obvious activity of promoting osteoblast mineralization and anti-bone metabolism activity, can be used for preparing an osteoblast activator, and can be used for preparing a bone repair material. And the compound has a good application prospect in the aspect of preparing medicines for preventing and / or treating bone metabolic diseases.
Owner:THIRD INSTITUTE OF OCEANOGRAPHY STATE OCEANI C ADMINISTRATION

Modulators of beta catenin and uses thereof

PCT designated stageWO2026112144A1Organic active ingredientsAntiinfectivesDiseaseBeta-catenin
Provided are compounds of the Formula I: or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.
Owner:DEWPOINT THERAPEUTICS INC

Small molecule inhibitor for targeting beta-catenin / BCL9 protein-protein interaction

The invention provides a small molecule inhibitor for targeting beta-catenin / BCL9 (Beta-catenin) protein-protein interaction. Specifically, the invention provides a compound or a pharmaceutically acceptable salt thereof, the compound is shown as a formula (I), and each variable is defined in the text.
Owner:JIANGSU MINGSHENG JUTAI BIOTECHNOLOGY CO LTD

Peptide inhibitors targeting the tbl1-beta-catenin complex

The present invention relates to a method of treating cancer in a subject, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a first peptide, wherein the first peptide comprises a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-33, 52-65, and function-conservative variants thereof. Also provided is a pharmaceutical composition for the treatment of cancer, the pharmaceutical composition comprising: a first peptide, wherein the first peptide comprises a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-33, 52-65, and function-conservative variants thereof.
Owner:TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Peptide having activity of promoting hair growth and inhibiting alopecia and use thereof

PendingCN121866264ACosmetic preparationsHair cosmeticsDermal papillaeCatenin Proteins
The invention relates to a peptide capable of promoting hair growth and preventing and inhibiting alopecia and application thereof. The peptide provided by the invention has the following activities: promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhancing the expression level of growth factor-related genes, enhancing the expression level of beta-catenin downstream genes, reducing the expression level of alopecia protein DKK-1, and promoting the growth of the hair follicle dermal papilla cells. Increasing the expression of keratin in hair outer root sheath cells (HORSC), and increasing the expression of transcription factors involved in cell activation in hair growth stromal cells (GMC); and promoting differentiation of hair follicle stem cells (HFSC).
Owner:CAREGEN

Multivalent FZD4, WNT co-receptor, and VEGF receptor molecules and uses thereof

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.
Owner:MERCK SHARP & DOHME LLC +1

Application of Wnt / beta-catenin inhibitor in preparation of medicine for treating myocardial infarction

The invention provides an application of a Wnt / beta-catenin inhibitor in preparation of a medicine for treating myocardial infarction, and belongs to the technical field of biological medicines. And the Wnt / beta-catenin inhibitor is KYA1797K, and the Wnt / beta-catenin inhibitor is KYA1797K According to the application disclosed by the invention, the expression of beta-catenin protein is successfully inhibited through a KYA1797K targeted Wnt / beta-catenin pathway, the cardiac function of a myocardial infarction mouse is remarkably improved, and the left ventricular ejection fraction (EF) and the left ventricular shortening fraction (FS) are remarkably recovered, so that the Wnt / beta-catenin inhibitor KYA1797K has a good treatment effect on myocardial infarction. In addition, a myocardial fibrosis area of a KYA1797K treatment group is obviously reduced, which indicates that the KYA1797K has an anti-myocardial fibrosis effect. The development result further proves the potential application value in myocardial infarction treatment.
Owner:NANJING FIRST HOSPITAL

Methods and compositions for treating ctnnb1-related disorders

The present invention relates to methods and compositions comprising RNAi agents (e.g., double-stranded RNA (dsRNA) agents) that target the beta-catenin (CTNNB1) gene for the treatment of CTNNB1-related disorders, such as cancer, such as hepatocellular carcinoma and colorectal cancer. The invention also relates to RNAi agents (e.g., double-stranded RNA (dsRNA) agents) that target the beta-catenin (CTNNB1) gene in combination with one or more therapeutic and / or therapeutic agents (e.g., immunotherapeutic agents, e.g., one or more immune checkpoint inhibitors, e.g., PD-1 inhibitors (e.g., anti-PD-1 antibodies or antigen binding fragments thereof), PD-L1 inhibitors, CTLA-4 inhibitors; and / or a VEGF inhibitor for use in the treatment of a subject having a CTNNB1-related disorder, such as cancer, such as hepatocellular carcinoma and colorectal cancer.
Owner:ALNYLAM PHARMACEUTICALS INC

Multivalent FZD4, WNT co-receptor, and VEGF receptor molecules and uses thereof

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.
Owner:EYEBIOTECH LTD +1

Multivalent FZD4, WNT co-receptor, and VEGF binding molecules and uses thereof

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.
Owner:MERCK SHARP & DOHME LLC +1

Graphene oxide-based composition for preventing or alleviating hair loss

The present disclosure relates to a graphene oxide-based a composition for preventing hair loss or promoting hair growth, including a graphene oxide. According to embodiments of the present disclosure, a composition for preventing hair loss or promoting hair growth may exhibit excellent effects in promoting the growth or proliferation of human follicle dermal papilla cells, in enhancing the expression or activity of hair growth-promoting factor proteins in human follicle dermal papilla cells, and in improving the expression or activity of Wnt / β-catenin. Also, the composition shows superior suppression of hair loss-inducing gene expression. Thus, the composition exhibits excellent effects in preventing hair loss or promoting hair growth.
Owner:QARBONX INC +1

Multivalent FZD4, WNT co-receptor, and VEGF binding molecules and uses thereof

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.
Owner:EYEBIOTECH LTD +1

Composition for promoting hair growth or inhibiting, preventing or alleviating alopecia, comprising peptide as active ingredient

PendingCN122028928ACosmetic preparationsHair removalDermal papillaeCatenin Proteins
The peptide of the present invention has the activity of promoting the proliferation of hair follicle dermal papilla cells (HFDPC); the composition can be used for activating cell proliferation related signal transduction protein and beta-catenin, up-regulating the expression level of growth factor related genes, up-regulating the expression level of beta-catenin subgenes and down-regulating the expression level of alopecia protein DKK-1 in human dermal papilla cells; increasing the expression of keratin in hair outer root sheath cells (HORSC); enhancing expression of transcription factors involved in cell activation in HGMC (Hair Growth Matrix Cells); and promoting differentiation of hair follicle stem cells (HFSC). Therefore, the peptide of the present invention can be used to promote hair growth or to inhibit, prevent, alleviate or treat alopecia.
Owner:CAREGEN

AUTAC bionic nano-particle, preparation method and application of AUTAC bionic nano-particle

The invention provides an AUTAC bionic nano-particle as well as a preparation method and application of the AUTAC bionic nano-particle. The nanoparticle has a core-shell structure, and sequentially comprises a core, a functional peptide layer and a cell membrane shell from inside to outside, the core comprises a PLGA-PEG-Mal copolymer carrier, and entrapped temozolomide and cationic lipid DOTAP (Dioctyl Terephthalate); the functional peptide layer is formed by covalently connecting a multifunctional peptide with a maleimide group through sulfydryl; the cell membrane shell is a microcolloid cell membrane; the nanoparticles can efficiently pass through a blood brain barrier, are enriched at a brain tumor part in a targeted manner, reduce MGMT expression by degrading beta-catenin, reverse TMZ drug resistance and enhance a chemotherapy effect, and are suitable for treating temozolomide drug-resistant glioblastoma.
Owner:金凤实验室

Compositions and methods for treating endometriosis

PendingUS20260098059A1Peptide/protein ingredientsSkeletal disorderMedicineCatenin Proteins
Provided herein are peptides that bind β-catenin, and compositions comprising said peptides. Peptides binding β-catenin prevent translocation to the nucleus and modulate the canonical Wnt pathway. Also provided herein are methods of using said peptides and compositions in the treatment of tissue-infiltrating conditions including endometriosis.
Owner:ENDOMET BIOSCIENCES INC